HAVCR2 and mesothelioma: The research has proven that TIM-3 is frequently expressed in programmed death ligand-1 mesothelioma tumors and that better longevity after the anti-CTLA4 therapies is attributed to reduced transcription of TIM-3; as an outcome, determining the involvement of TIM-3 may be a plausible prognostic variable to anticipate patients who will respond to therapy (140).